CAMARILLO, Calif., July 17, 2026 (GLOBE NEWSWIRE) — Salem Media, Inc. (OTCQX: SALM) announced a leadership transition for Salem Surround, the company’s digital marketing agency, as longtime Salem executive Jon Latzer prepares to retire following his many years of service to the company.Latzer has been instrumental in the growth of Salem Surround, helping expand the company’s digital marketing capabilities while supporting local markets, sales teams, clients, and vendor partnerships across the country. His leadership has helped position Salem Surround as a key part of Salem’s broader digital strategy. “Jon has been a tremendous leader and trusted partner throughout his time at Salem,” said Jamie Cohen, Chief Digital Officer of Salem Media. “He has helped shape Salem Surround into the business it is today through...

TORONTO, July 17, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND IL-32 chronic kidney disease (“CKD”) program. The U.S.-based lab was selected for its core competencies in the areas required to support the IL-32 program. It will perform studies on behalf of Arch to generate proprietary data and support the Company’s patent portfolio covering its IL-32 drug candidates and related method-of-use claims. These studies represent the next stage of drug development following the identification of IL-32 as a potential therapeutic target in diabetic kidney disease. “This research contract is an important step in advancing the Company’s IL-32 CKD drug development program,” said...

Series  RIKB 38 0215 RIKS 29 0917Settlement Date  07/22/2026 07/22/2026Total Amount Allocated (MM)  4,510 1,350All Bids Awarded At (Price / Yield)  96.725 / 6.910 99.725 / 3.591Total Number of Bids Received  23 5Total Amount of All Bids Received (MM)  5,310 1,350Total Number of Successful Bids  19 5Number of Bids Allocated in Full  19 5Lowest Price / Highest Yield Allocated  96.725 / 6.910 99.725 / 3.591Highest Price / Lowest Yield Allocated  97.000 / 6.880 99.810 / 3.562Lowest Price / Highest Yield Allocated in Full  96.725 / 6.910 99.725 / 3.591Weighted Average of Successful Bids (Price/Yield)  96.803 / 6.900 99.738 / 3.586Best Bid (Price / Yield)  97.000 / 6.880 99.810 / 3.562Worst Bid (Price / Yield)  96.420 / 6.950 99.725 / 3.591Weighted Average of All Bids Received (Price / Yield)  96.776 / 6.910 99.738 / 3.586Percentage...

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees. The Inducement Grants were granted pursuant to Artiva’s 2025 Inducement Plan (the “Inducement Plan”), and were effective July 14, 2026. The Inducement Grants will vest over four years, with vesting aligned to quarterly vesting dates of February 15, May 15, August 15 and November 15 (the “Quarterly Vesting Dates”). For each new employee, 25% of the Inducement Grant will...

LINCOLNSHIRE, Ill., July 17, 2026 (GLOBE NEWSWIRE) — Camping World Holdings, Inc. (NYSE: CWH) (the “Company”) today announced that its financial results for the second quarter 2026 will be released after the market closes on Wednesday, July 29, 2026. The Company will host a conference call on Thursday, July 30, 2026 at 7:30 a.m. Central Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 800-717-1738 (international callers please dial 1-646-307-1865) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at http://investor.campingworld.com. A taped replay of the conference call will be available within two hours of the conclusion of the call and can be accessed both online and by...

Strong Consumer Response Drives Expanded Seasonal Merchandising Initiative Across Participating ShopRite Locations BELVIDERE, N.J., July 17, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that Wakefern Food Corp. is expanding the Company’s Garden Starters pallet display program with a new midsummer promotional event across participating ShopRite locations. Building on strong customer response during the spring season, the expanded promotion is designed to meet continued consumer demand for fresh, living herbs while encouraging home gardening and outdoor entertaining throughout...

Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, today noted the significant regulatory and inter-agency developments this week supporting the development of innovative treatments for serious neuropsychiatric and addiction disorders. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: “At a time when patients in the veterans community and the general population have too few treatment options for intractable neuropsychiatric and addiction disorders, we are grateful that Secretary Kennedy is looking to transform treatment opportunities through the expansion of new therapeutic approaches.” This week’s developments include...

Schindellegi, Switzerland – 17 July 2026 Trifork Group AGCompany announcement no. 42/2026 Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation Article 19, Trifork Group AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork or persons closely associated with them.1. Details of the person discharging managerial responsibilities/person closely associateda) Name Anja Monrad2. Reason for the notificationa) Position/status Chairperson of the Board of Directorsb) Initial notification/Amendment Initial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction...

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responsesCOPENHAGEN, Denmark, July 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27,...

Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in vision and retinal...